The concentration of human β-endorphin (βh-EP) was measured in various hypothalamic nuclei, in extra-hypothalamic brain regions and in the anterior and posterior lobes of the pituitary using a specific radioimmunoassay (RIA). The βh-EP concentrations in the arcuate nucleus (169 ± 35 pg/100 μ g protein, n = 7) and median eminence (163 ± 32 pg/100 μ g protein, n = 6) were among the highest in the 17 brain areas examined. The immunoreactive βh-EP in the hypothalamus corresponded to authentic βh-EP, as determined by gel exclusion chromatography. By chromatography and RIA the βh-EP concentrations in anterior (1.53 × 105 ±0.51 × 105 pg/100 μ g protein, n = 3) and posterior (1.41 × 105 ± 0.38 × 105 pg/100 μ g protein, n = 5) pituitary were found to be approximately 1,000-fold higher than in hypothalamus. Within the pituitary βh-EP was localized throughout the anterior lobe, in the pars intermedia and in that part of the posterior lobe nearest the pars intermedia, as judged by immunocytochemistry. Dense immunocytochemical staining was found along the perimeter of many blood vessels. βh-EP and adrenocorticotropin (ACTH) were co-localized in the same pituitary cells. The present data represent the first unequivocal localization and quantitation of βh-EP in human brain and in the separate lobes of the human pituitary.

Keywords:
β-Endorphin, Hypothalamic nuclei, Pituitary lobes, Radioimmunoassay, Gel chromatography, Immunocytochemistry
This content is only available via PDF.
© 1980 S. Karger AG, Basel
1980
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.